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Abstract
Background: When cyclophosphamide and preparations of fragmented exogenous genomic double stranded DNA were
administered in sequence, the regressive effect on the tumor was synergic: this combined treatment had a more pronounced
effect than cyclophosphamide alone. Our further studies demonstrated that exogenous DNA stimulated the maturation and
specific activities of dendritic cells. This suggests that cyclophosphamide, combined with DNA, leads to an immune response to
the tumors that were grafted into the subjects post treatment.
Methods: Three-month old CBA/Lac mice were used in the experiments. The mice were injected with cyclosphamide (200
mkg per 1 kg body weight) and genomic DNA (of human, mouse or salmon sperm origin). The DNA was administered
intraperitoneally or subcutaneously. After 23 to 60 days, one million tumor cells were intramuscularly grafted into the mice. In
the final experiment, the mice were pre-immunized by subcutaneous injections of 20 million repeatedly thawed and frozen
tumor cells. Changes in tumor growth were determined by multiplying the three perpendicular diameters (measured by caliper).
Students' t-tests were used to determine the difference between tumor growth and average survival rate between the mouse
groups and the controls.
Results: An analysis of varying treatments with cyclophosphamide and exogenous DNA, followed by tumor grafting, provided
evidence that this combined treatment had an immunizing effect. This inhibitory effect in mice was analyzed in an experiment
with the classical immunization of a tumor homogenate. The strongest inhibitory action on a transplanted graft was created
through the following steps: cyclophosphamide at 200 mg/kg of body weight administered as a pretreatment; 6 mg fragmented
exogenous DNA administered over the course of 3 days; tumor homogenate grafted 10 days following the final DNA injection.
Conclusion: Fragmented exogenous DNA injected with cyclophosphamide inhibits the growth of tumors that are grafted to
mice after this combined treatment.
Published: 14 August 2009
Genetic Vaccines and Therapy 2009, 7:12 doi:10.1186/1479-0556-7-12
Received: 1 June 2009
Accepted: 14 August 2009
This article is available from: http://www.gvt-journal.com/content/7/1/12
© 2009 Alyamkina et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Genetic Vaccines and Therapy 2009, 7:12 http://www.gvt-journal.com/content/7/1/12
Page 2 of 11
(page number not for citation purposes)
Background
There is considerable interest in immunomodulatory oli-
gonucleotides (IMOs) that either contain CpG motifs or
have a phosphorothioate backbone [1]. Experimental
data indicated that these DNA, when administered sys-
temically, were able to induce the adaptive immune
response. This property of IMOs is widely discussed in
terms of its use for cancer immunotherapy [2-6].
IMOs act as a stimulant on immunocompetent T-lym-
phocytes, natural killer cells, macrophages, and dendritic
cells (DCs). DCs are the primary target. IMOs, as an
inducer of DC immunocompetency (depending on con-
ditions), can exert both anticancer and suppressive influ-
ences. DCs treated with specific IMOs affect the direction
of differentiation in naive CD4+ CD25- T-cells [7,8].
There is experimental evidence indicating that the immu-
nogenic properties of IMOs are due to their effect on the
Toll-like receptors (TLRs) detected in large quantities in
plasmatic DCs and macrophages [9-11]. TLR9s are the
pattern-recognizing receptors that initiate the innate and
adaptive immunity. Interaction of DC TLR9 with a specific
IMO ligand is the first and crucial step in activating the
DC's ability to induce a biological anticancer effect; subse-
quently, the synthesis and secretion of main cytokines
and T-lymphocyte differentiation take place. When the
T8+ pathway is activated, DCs efficiently present antigens
(AGs) and tumor AGs to T-cytotoxic lymphocytes in order
to stimulate their proliferation. This leads to the forma-
tion of an anti-tumor adaptive immune response.
The regression stimulated by this cytostatic treatment syn-
ergize with subsequent IMO injections [4]. The anti-
tumor activities of specific nucleotides, when adminis-
tered immediately after cytostatic treatments, are consid-
erably augmented. It is imperative to strictly adhere to the
administration of cytostatics (including cyclophospha-
mide (CP)), followed by IMOs, in order to synergize the
components and increase their efficacy as a cancer treat-
ment.
The synergy of these components could stem from the
decreased number of regulatory T-lymphocytes (Tregs).
This decrease suppresses the Tregs' adaptive immunity,
and delays their development (in comparison to CD8+ T-
lymphocytes after myelosupression under cytostatic
effect). Another possible explanation for the synergistics is
that cytostatics enhance the immune response to tumor
AGs (thus altering their immunogenicity).
Inhibition of the Tregs antitumor response is presumably
a major obstacle to the success of tumor vaccinations and
immunotherapy [4,12]. Based on clinical trials, it may be
assumed that the efficacy of antitumor IMO therapy may
be boosted by a pre-inactivation of Tregs. Treatments with
cytostatics at therapeutic doses kill lymphocytes of all
types, irrespective of their properties. The results of many
studies provide evidence that Tregs may have a greater
sensitivity to cytostatics than normal T-cells [13-20]. It
thus appears that chemotherapy can selectively and
strongly alter Tregs, while sparing the viability of T-cyto-
toxic lymphocytes, which are the determinants of the high
anti-tumor efficiency of this therapy [17,21,22]. Tumor
microenvironments harbor the activity of Tregs, suppress-
ing the immune effect on tumor cells and thus protecting
the tumor from immune regression. In such a case, chem-
otherapy not only decreases the number of Tregs, but also
abolishes their defense function [14,20,23-25]. The
stripped nude tumor is rendered susceptible to the effect
of the innate and adaptive immunity induced by IMOs.
Tumor microenvironments actually change during spar-
ing treatment with cytostatics. DCs become activated and
form a T-cytotoxic response to the tumor (which had pre-
viously escaped immune surveillance [4]).
Our previous studies established that not only IMOs, in
combination with cytostatics, had a suppressive effect on
tumor development; tumor growth was also significantly
inhibited by a combined treatment of CP and human
genomic double stranded DNA (dsDNA) fragmented to
200–6000 bp [26]. This combined treatment was much
more effective than treatment with CP alone.
When exogenous DNA was used as a leukostimulator after
CP-induced myelosuppression, tumors that were grafted
post treatment were reduced. Combined treatment of CP
and DNA was successful at strongly suppressing growth of
tumor grafted before the treatment [26] and after it [this
study].
Our further studies demonstrated that fragmented exoge-
nous genomic dsDNA stimulates the maturation of DCs
and activates their specific activity [unpublished data]. We
suggest that treatment with CP and exogenous DNA leads
to activation of the immune system.
In recent experiments, we tested regimens of CP and frag-
mented genomic DNA administration. We also followed
the timeline of change in tumors that were grafted to mice
(pre-treated or not with AGs). CP injections, in combina-
tion with subsequent fragmented genomic dsDNA treat-
ments, provided evidence that this co-therapy had a
pronounced antitumor effect on tumor grafts.
Methods
Animals
Three-month old CBA/Lac mice that were bred at the ani-
mal facility of the Institute of Cytology and Genetics (the
Siberian Branch of the Russian Academy of Sciences) were
used in experiments. Mice in groups of 10 were housed inGenetic Vaccines and Therapy 2009, 7:12 http://www.gvt-journal.com/content/7/1/12
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plastic cages. They had free access to food and water. All
experiments were performed in accordance with protocols
approved by the Animal Care and Use Committee of the
Institute of Cytology and Genetics.
Preparations of DNA
Human DNA preparations were isolated from the placen-
tas of healthy women using a phenol-free method; this
made it possible to obtain a genome that preserves the
fragments that are in vivo associated with the nuclear
matrix (scaffold) proteins. The DNA preparation did not
contain histones and polysaccharides; it was endotoxin-
free. Mouse DNA was isolated from a mixture of tissues
(thymus, liver, kidneys, spleen) and salmon sperm DNA
was isolated from salmon sperm. DNA was fragmented in
an ultrasonic disintegrator at a frequency of 22 kHz, to
obtain a mixture of DNA fragments with a size of 200 to
6000 bp. DNA preparations were dissolved in saline and
stored at a temperature of -20°C.
Mouse treatment regimens
The mouse treatment regimens are schematically repre-
sented in the figures that can be found in the Results sec-
tion. CP (Veropharm, Russia) that was dissolved in saline
was injected intraperitoneally (i.p.). Mice received either
one CP injection (experiments 3–6) or two (experiments
1 and 2) on a daily interval. The total CP dose did not
exceed 200 mg per 1 kg of body weight. This was followed
by 3–12-fold administrations of 1 mkg – 2 mg DNA prep-
arations (of human, mouse or salmon sperm origin) that
were injected i.p. or subcutaneously (s.c.) into the backs
of mice for 1–3 days. In experiments 1 and 2, mice were
additionally i.p. injected with 1 mg DNA 30 min prior to
the CP injection, and they received 0.5 mg DNA during
the interval between the two CP injections (30–40 min
after the first CP dose). The control groups in experiments
1 and 5 were treated with saline instead of DNA or CP.
The control groups in experiment 1 were mice that
received either CP alone or DNA alone according to the
regimen given in Fig. 1. The control mice in experiment 5
were given CP 200 mg/kg two months before the tumors
were grafted. Tumor cells were grafted 23 – 60 days after
the last DNA administration. Groups of 6–10 mice were
used for each experiment.
Tumor models
We used Krebs-2 and lymphosarcoma (LS) tumors. The
transplantable mouse LS was induced by V.I. Kaledin
(Institute of Cytology and Genetics, Siberian Branch of
the Russian Academy of Sciences, Novosibirsk, Russia) in
CBA mice using nitrosomethylurea, transformed into an
ascitic form, and maintained in this line. LSs are highly
sensitive to the apoptosis induced by CP and several other
alkylating agents. The Krebs-2 tumors were initially
derived from mammary gland adenocarcinomas; they are
mouse nonspecific and do not spread by metastases.
Tumor cells (1 × 106) were grafted intramuscularly (i.m.)
into the right hind thigh of the mice. Changes in tumor
growth (cm3) were determined by multiplying the three
perpendicular diameters (measured by caliper). These
measurements were done 8–17 days after grafting.
Immunization experiment
In experiment 6, 10 days after the mice that were injected
with CP and human DNA were preimmunized with
tumor AGs (by s.c. injection into the dorsal back of 20 ×
106 repeatedly thawed-frozen Krebs-2 tumor cells), 1 ×
106 Krebs-2 tumor cells were grafted i.m. into the right
hind thigh of the mice. In this experiment, there were two
additional control groups; one was immunized only, and
the other was immunized after the CP injection.
Statistical analysis
Students' t-tests were used to determine the significance of
the differences in tumor growth, and average survival
Tumor growth (mean ± SEM) in mice treated with CP and  human DNA, comparing the regimen shown below with the  control (n = 10) Figure 1
Tumor growth (mean ± SEM) in mice treated with 
CP and human DNA, comparing the regimen shown 
below with the control (n = 10). Mice received two CP 
injections (100 mg per 1 kg body weight) at a daily interval; 
0.5–1 mg human DNA was administered i.p. or s.c. to the 
mice. The control group was injected with saline. The addi-
tional control groups received either CP alone or DNA 
alone according to the regimen. Krebs-2 tumor cells were 
grafted i.m. 23 days after the last DNA administration.Genetic Vaccines and Therapy 2009, 7:12 http://www.gvt-journal.com/content/7/1/12
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between the mouse groups and the controls. All results
were expressed as mean ± SEM.
Results
Suppression of growth of experimental tumors in regimens 
of CP injection and exogenous dsDNA administration
We estimated the co-treatment effect of cytostatic CP,
combined with a preparation of exogenous fragmented
dsDNA, on the growth of experimental tumors in mice. At
the early phase of the experiment, we chose the parame-
ters for CP injections, exogenous DNA administrations,
and tumor grafting with the following considerations.
The activating effect of exogenous DNA on the immune
system was estimated first. For this reason, all treatments
were done prior to tumor grafting. Moreover, we had
established that the administration of exogenous dsDNA,
30–60 min before or after the CP injection, had no statis-
tically significant effect on tumor growth suppression
[26]. The retardation of the grafted tumor growth became
conspicuous when the interval between DNA administra-
tion and CP injection was long (1–3 days after CP injec-
tion). Several administrations of exogenous dsDNA for 1–
3 days after CP injections most efficiently suppressed
tumor growth [26].
With the above parameters, we designed experiments for
immune system activation in treated mice. The design
included CP injections, administrations of exogenous
DNA preparation and tumor grafting after different time
intervals.
Estimation of the effect of regimens of CP plus exogenous 
fragmented dsDNA on tumor growth
We proceeded to examine the effect of CP injections or
fragmented human dsDNA administrations prior to graft-
ing Krebs-2 tumors (Experiment 1). As shown in Fig. 1,
the effect of only CP or DNA on the tumor was statistically
insignificant (p > 0.05, n = 10).
In our further experiments, we used versions of CP injec-
tions combined with administrations of fragmented exog-
enous DNA. Fig. 2 presents the three regimens for
cytostatic injections and administrations of exogenous
DNA (Experiment 2). The strongest suppressive effect on
the grafted Krebs-2 tumor was created by Regimen 1 (p <
0.001, n = 10): CP was injected two times in combination
with DNA (after defined intervals), and tumor were
grafted 3 weeks – 1.5 months (the experiment was repli-
cated several times) after the last DNA administration.
The treatment protocol followed in Regimen 2 differed
from Regimen 1 in that the mice received four additional
exogenous DNA injections after the tumor grafting; this
completely abolished the suppressive effect of the Regi-
men 1 therapy and induced the progression of the graft.
We believe that the number and function of Tregs
immune suppressors recovered by the time we started to
repeatedly administer exogenous DNA. Injected exoge-
nous DNA had already driven the adaptive response
toward the Tregs phenotype; this led to suppression of the
initially activated immune response and tumor progres-
sion.
Four administrations of exogenous DNA preparations
according to Regimen 3 (after the tumor grafting only)
had a weaker effect than Regimen 1; however, they had a
significant (p < 0.05, n = 10) effect on Krebs-2 tumor
growth in comparison with the controls.
18–30 h after systemic CP injections, interstrand
crosslinks begin to repair from start to finish. These cross
links are a result of human fragmented DNA presumably
integrating extensively into the genome of the experimen-
tal mice. This integration was lethal for most mice [27]. To
estimate how this effect may concern a synergic coopera-
tion of the two agents, we performed Experiment 3 using
a new regimen for combined treatment with cytostatic
and DNA (Fig. 3). Mice received human DNA prepara-
tions every hour for 12 h after CP injections (Regimen 4)
and hourly for 6 h, 13–18, 19–24, 25–30, and 31–36 h
after CP injections (6 mice per group).
It was found that survival significantly improved (p <
0.05, n = 6) in groups 1 and 5 (mice that were treated with
DNA1-13 and 31–36 h after the CP injection) compared
with those of the control group (Table 1). It was also
found that survival of group 4 (25–30 h) was insignifi-
cantly shorter (p > 0.05, n = 6: by 12%) than the control
group. We believe that the reduced survival rate after the
treatments during this interval was due to the extensive
integration of exogenous DNA fragments into the
genomes of treated mice, which uncoupled primary vital
systems and developed diseases that lead to death.
The increased survival rate of groups 1 and 5 can be
explained through the timing of the repair mechanism: it
did not start at the first time interval, but it was consum-
mate at the second. Thus, exogenous DNA could not inte-
grate, and DNA stimulated DCs and an increased immune
response caused a statistically significant increase (p <
0.05, n = 6) in survival.
Regimen 4 was not substantially different from the gen-
eral outline described in the beginning of the section. Its
set of experiments resulted with the persistent suppression
of grafted tumors. Its efficiency is comparable to that
obtained with Regimen 1.
Using Regimen 4, we estimated the inhibitory effect of
single and multiple hourly administrations of exogenousGenetic Vaccines and Therapy 2009, 7:12 http://www.gvt-journal.com/content/7/1/12
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Tumor growth (mean ± SEM) in mice treated with CP and human DNA, comparing the regimen shown below with the control  (n = 10) Figure 2
Tumor growth (mean ± SEM) in mice treated with CP and human DNA, comparing the regimen shown below 
with the control (n = 10). Mice received two CP injections (100 mg per 1 kg body weight) on a daily interval; 0.5–1 mg 
human DNA were administered i.p. or s.c. to the mice. The control group was injected with saline. Krebs-2 tumor cells were 
grafted i.m. 1.5 month after the last DNA administration. The other group (2) received four human DNA s.c. injections after 
the tumor grafting. And the last group (3) didn't received CP but only four administrations of exogenous DNA preparations 
after the tumor grafting.Genetic Vaccines and Therapy 2009, 7:12 http://www.gvt-journal.com/content/7/1/12
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DNA preparations for 12 h after the CP injection (data not
shown). Evidence indicated that multiple administrations
of DNA preparation 0–12 h after the CP injection led to
suppressed tumor growth. Vice versa, a single exogenous
DNA administration at different times for 1–12 h after the
CP injection had no suppressive effect on the growth of a
grafted Krebs-2 tumor.
Analysis of a dose-dependent suppressive effect (with
dsDNA preparations) provided evidence that 10–100 mkg
was an efficient dose (p < 0.005, n = 7) to suppress tumor
growth, while 1 mkg per mouse insignificantly suppressed
tumor growth (p > 0.05, n = 7) (Experiment 4, Fig. 4).
Overall, the preparations increased the average mice sur-
vival insignificantly (p > 0.05, n = 7) (Table 2). The DNA
used in this experiment was allogenic, obtained from CBA
mice.
Estimation of the effect of exogenous DNA from different 
organisms on tumor growth on the background of CP 
therapy
In Experiment 5, we analyzed the effect of exogenous
DNA based on its species origin (Fig. 5). Regimen 4 was
chosen for obtaining estimates. The results showed that
human xenogenic DNA combined with CP injections had
the strongest statistically significant suppressive effect (p <
0.005, n = 6) on grafted tumor development, compared to
allogenic mouse DNA (p < 0.05, n = 6) and distantly
related DNA derived from salmon sperm (p < 0.05, n = 6).
Tumor growth (mean ± SEM) in mice treated with CP and human DNA, comparing the regimens shown below with the con- trol (n = 6) Figure 3
Tumor growth (mean ± SEM) in mice treated with CP and human DNA, comparing the regimens shown 
below with the control (n = 6). Mice received CP injections (200 mg per 1 kg body weight); 1 (1), 13 (2), 19 (3), 25 (4), 31 
(5) h after 1 mg DNA was administered i.p. every hour, 12 (1) or 6 (2–5) times. The control group was injected with saline. LS 
tumor cells were grafted i.m. 1 month after the last DNA administration.Genetic Vaccines and Therapy 2009, 7:12 http://www.gvt-journal.com/content/7/1/12
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Estimation of immunization intensity for sequential 
treatment with cytostatic and exogenous genomic dsDNA
In Experiment 6, mice were additionally immunized with
a tumor cell homogenate after CP and exogenous DNA
(Fig. 6). This co-treatment had the strongest suppressive
effect on the grafted tumor in comparison to the control
(p < 0.001, n = 10). The solitary immunizations and the
immunizations with CP, without DNA, were weaker.
Comparing the volumes of Krebs-2 tumors grafted accord-
ing to Regimen 1 (Experiment 2) with those immunized
additionally in the interval between the last DNA admin-
istration and grafting (Experiment 6) demonstrated that
immunization enhanced the suppressive effect on tumor
growth (Fig. 7). The following regimen exerted the strong-
est inhibitory action on the graft: pre-treatment with CP at
200 mg/kg of body weight; fragmented exogenous DNA
given for 3 days at a total dose of 6 mg; tumor homoge-
nate injected 10 days after last DNA injection.
Discussion
The present results evidence that exogenous DNA admin-
istered to experimental mice in combination with the
cross linked cytostatic CP has an immunizing action and
suppresses growth of a tumor that is grafted after this
treatment. This means that CP/exogenous DNA co-treat-
ments prepare the immune system to give a rapid specific
immune response when tumor AGs arise. This co-treat-
ment activates the immune system to acquire the ability to
recognize tumor AGs and respond efficiently. The results
of our concomitant study disclosed that this observed
property of exogenous DNA is due to activation of DC
maturation and a drive of the adaptive response toward
cytotoxic T-cells [unpublished data].
Table 1: Average survival of mice in Experiment 3.
Group Survival, days
Control 18.7 ± 0.8
12 2 . 1  ±  1 . 2
21 8 . 2  ±  1 . 4
31 9 . 0  ±  1 . 1
41 6 . 4  ±  0 . 2
52 4 . 2  ±  2 . 0
The values are means ± SEM (n = 6).
Tumor growth (mean ± SEM) in mice treated with CP and different doses of mouse DNA, comparing the regimen shown  below with the control (n = 7) Figure 4
Tumor growth (mean ± SEM) in mice treated with CP and different doses of mouse DNA, comparing the reg-
imen shown below with the control (n = 7). Mice received CP injections (200 mg per 1 kg body weight); 18 h afterward 1 
mkg (1) or 10–100 mkg (2) mouse DNA was administered i.p. every hour 12 times. The control group was injected with saline. 
LS tumor cells were grafted i.m. 2 months after the last DNA administration.Genetic Vaccines and Therapy 2009, 7:12 http://www.gvt-journal.com/content/7/1/12
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Experiments designed to elucidate the synergic suppres-
sive effect of cytostatics and immunomodulatory DNAs
(which CpG DNA with a normal sugar phosphate back-
bone and oligonucleotides whose backbone sugar phos-
phorothioate belong to) are widely discussed. To our
knowledge, all studies have attributed this synergic sup-
pressive effect to the activation of both the innate immune
and (more frequently) the adaptive immune response to
the spreading tumor tissue. Differentiated suppression of
Tregs and CD8+ T-cytotoxic lymphocytes under the effect
of cytostatic, in the case of CP and IMOs (CpG) co-ther-
apy, leads to activation of the innate and adaptive immu-
nity.
Tumors induce the rapid capture of Tregs and Tregs-pro-
duced cytokines that inhibit the adaptive immunity [28-
30]. CP creates and defines conditions for the differenti-
ated suppression of T-cytotoxic and T-regulatory lym-
phocytes, and there exists an interval when the CD8+ T-
cells: Tregs ratio becomes skewed by an order of two mag-
nitudes in favor of T killer cells [14,15,17,18,23,28,31,
32]. The difference in suppression degree and recovery
rate between CD8+ lymphocytes and Tregs is important to
cancer therapy. This is the time when the tumor becomes
detectable by the non-supressed immune system. Tumor
AGs are presented on DCs, and the surviving CD8+ T-lym-
phocytes (those not under the effect of cytokines pro-
duced by Tregs) kill cells of the developing tumor [23].
In the experimental studies, mice received CP after the
tumors' stable growth. Tumor cells were left to die for
some days after cytostatic treatment [33]. It was thought
that at this time DCs absorbed apoptotic bodies of dead
Table 2: Average survival of mice in Experiment 4.
Group Survival, days
Control 18.7 ± 0.8
12 5 . 0  ±  3 . 4
22 3 . 1  ±  2 . 0
The values are means ± SEM (n = 7).
Tumor growth (mean ± SEM) in mice treated with CP and DNA preparations human, mouse or salmon sperm origin, compar- ing the regimen shown below with the control (n = 6) Figure 5
Tumor growth (mean ± SEM) in mice treated with CP and DNA preparations human, mouse or salmon sperm 
origin, comparing the regimen shown below with the control (n = 6). Mice received CP injections (200 mg per 1 kg 
body weight); 18 h afterward saline ("CP") or 1 mg of genomic DNA preparations of mouse ("CP + mDNA"), salmon sperm 
("CP + ssDNA") or human ("CP + hDNA") DNA were administered i.p. every hour for 12 times. The control group was 
injected with saline. Krebs-2 tumor cells were grafted i.m. two months after the last DNA administration.Genetic Vaccines and Therapy 2009, 7:12 http://www.gvt-journal.com/content/7/1/12
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tumor cells or DNA of another kind as a result of lysed
tumor cells. The adaptive immune response was simulta-
neously stimulated by IMOs via the CD8+ T-cell pathway;
this led to active presentation of tumor AGs and the pro-
liferation of lymphocytes [1,14,20,23-25,33-37].
In the studies, we used a novel regimen. Mice were first
treated with a combination of CP and a human frag-
mented dsDNA preparation; this was followed by tumor
grafting. With this treatment, the growth of many grafted
tumor cells was substantially suppressed. To reiterate, our
previous study had shown that the dsDNA preparation
activates DCs ex vivo and induces their maturation and
allostimulatory activity [unpublished data]; it is precisely
this link of the immune system that activates tumor sup-
pression.
In the experiments, doses of CP were therapeutic standard
(200 mg/kg). The results clearly showed that the suppres-
sive effect on tumor progression was manifested in all the
experiments. This was due to activation of DCs by exoge-
nous DNA, which in turn induced the adaptive immunity.
Since CP at the applied doses completely eliminated both
CD8+ T-cells and Tregs, exogenous DNA presumably acti-
vated DCs in such a way that just the T-cytotoxic adaptive
(not the Treg suppressive) immune response was acti-
vated. This suggested that cytostatic and exogenous DNA
combined treatments did not need a reduction in doses of
CP for suppression of the two lymphocyte types; CP can
be used at doses approved in modern practice; and the
adaptive immune response is inducible at a defined time
with exogenous dsDNA preparations.
Exogenous DNA activates the adaptive immune system 1–
3 days after the injection of CP, resulting in suppression of
the grafted tumor. We chose to graft the tumors 1–2
months after the last administration of the exogenous
DNA preparations based on our experience. There may be
other time intervals used to achieve a stronger suppressive
action on tumors.
With the literary data taken into consideration, there are
grounds to believe that pre-treatments with CP and exog-
Tumor growth (mean ± SEM) in mice treated with CP and  human DNA, comparing the regimen shown below with the  control (n = 10) Figure 6
Tumor growth (mean ± SEM) in mice treated with 
CP and human DNA, comparing the regimen shown 
below with the control (n = 10). Mice received CP injec-
tions (200 mg per 1 kg body weight); 30 min afterward and 
during the consecutive two days, mice were injected with 
human DNA, 1 mg i.p. and 1 mg s.c.. Mice were preimmu-
nized with tumor AGs by s.c. injection into the dorsal back of 
20 × 106 repeatedly thawed-frozen Krebs-2 tumor cells 10 
days after the last DNA administration; 10 days after immuni-
zation 1 × 106 Krebs-2 tumor cells were grafted i.m. into the 
right hind thigh of mice. The control group was injected with 
saline. There were two additional control groups; one was 
immunized only, and the other was immunized after the CP 
injection.
Tumor growth (mean ± SEM) in mice treated according to  Regimen 1 and additionally immunized (n = 10) Figure 7
Tumor growth (mean ± SEM) in mice treated 
according to Regimen 1 and additionally immunized 
(n = 10). The control group was injected with saline. In Reg-
imen 1, mice received two CP injections (100 mg per 1 kg 
body weight) on a daily interval; 0.5–1 mg human DNA were 
administered i.p. or s.c. Krebs-2 tumor cells were grafted i.m. 
1.5 month after the last DNA administration. Regimen 1 + 
immunization, mice received CP injection (200 mg per 1 kg 
body weight); 30 min afterward and during the consecutive 
two days, mice were injected with human DNA, 1 mg i.p. and 
1 mg s.c.. Mice were pre-immunized with Krebs-2 tumor 
AGs by a s.c. injection 10 days after the last DNA administra-
tion; Krebs-2 tumor cells were grafted i.m. 10 days after 
immunization. Immunization enhanced the suppressive effect 
on tumor growth.Genetic Vaccines and Therapy 2009, 7:12 http://www.gvt-journal.com/content/7/1/12
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enous DNA create an environment with effecter T-lym-
phocytes and DNA-activated DCs. This is after CP-
induced myelosuppression is affected through the prolif-
eration induction of cytotoxic, not suppressor, T-lym-
phocytes.
Conclusion
Injections of fragmented exogenous DNA, combined with
CP, inhibit the growth of tumors that are grafted to mice
post treatment. It is assumed that this observed property
of exogenous DNA is due to activation of DC maturation
and a drive of the adaptive response toward cytotoxic T-
cells.
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